Results from cell culture studies suggest a class of anticancer compounds called EGFR inhibitors, largely written off for breast cancers, could be effective in obese patients. The hormones leptin and IGF-1 synergistically stimulate migration and invasion in breast cancer cells. EGFR inhibitors block this stimulation.